{"title":"一个不希望的副作用:慢性丙型肝炎病毒诱导的肝硬化患者在雷地帕韦/索非布韦治疗后发生巨大的肝细胞癌","authors":"T. Sahin, A. Serin","doi":"10.5606/FNG.TRANSPLANTASYON.2018.002","DOIUrl":null,"url":null,"abstract":"Hepatocellular carcinoma (HCC) is the fifth common cancer and the second cause of cancer-related death worldwide. Hepatitis C virus (HCV) is a common cause of chronic hepatitis, liver cirrhosis, and HCC. Recently, some new drugs have been developed named direct-acting antivirals (DAAs) for chronic HCV treatment. Direct-acting antivirals provide sustained viral response and total cure in over 80% of chronic hepatitis C patients. In this article, we present a patient with HCV genotype 1b-induced cirrhosis with giant HCC development after ledipasvir/sofosbuvir combination therapy. Although chronic hepatitis C infection can be cured with the combination of new generation DAAs, HCC pathogenesis and development risk in cirrhotic cases are still unclear. Thus, cirrhotic patients treated with DAAs should be followed-up at close intervals after treatment.","PeriodicalId":333292,"journal":{"name":"Demiroglu Bilim University Florence Nightingale Transplantation Journal","volume":"55 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2019-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"An unwanted side effect: Giant hepatocellular carcinoma development after ledipasvir/sofosbuvir therapy in a chronic hepatitis C virus-induced cirrhotic patient\",\"authors\":\"T. Sahin, A. Serin\",\"doi\":\"10.5606/FNG.TRANSPLANTASYON.2018.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Hepatocellular carcinoma (HCC) is the fifth common cancer and the second cause of cancer-related death worldwide. Hepatitis C virus (HCV) is a common cause of chronic hepatitis, liver cirrhosis, and HCC. Recently, some new drugs have been developed named direct-acting antivirals (DAAs) for chronic HCV treatment. Direct-acting antivirals provide sustained viral response and total cure in over 80% of chronic hepatitis C patients. In this article, we present a patient with HCV genotype 1b-induced cirrhosis with giant HCC development after ledipasvir/sofosbuvir combination therapy. Although chronic hepatitis C infection can be cured with the combination of new generation DAAs, HCC pathogenesis and development risk in cirrhotic cases are still unclear. Thus, cirrhotic patients treated with DAAs should be followed-up at close intervals after treatment.\",\"PeriodicalId\":333292,\"journal\":{\"name\":\"Demiroglu Bilim University Florence Nightingale Transplantation Journal\",\"volume\":\"55 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-04-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Demiroglu Bilim University Florence Nightingale Transplantation Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5606/FNG.TRANSPLANTASYON.2018.002\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Demiroglu Bilim University Florence Nightingale Transplantation Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5606/FNG.TRANSPLANTASYON.2018.002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
An unwanted side effect: Giant hepatocellular carcinoma development after ledipasvir/sofosbuvir therapy in a chronic hepatitis C virus-induced cirrhotic patient
Hepatocellular carcinoma (HCC) is the fifth common cancer and the second cause of cancer-related death worldwide. Hepatitis C virus (HCV) is a common cause of chronic hepatitis, liver cirrhosis, and HCC. Recently, some new drugs have been developed named direct-acting antivirals (DAAs) for chronic HCV treatment. Direct-acting antivirals provide sustained viral response and total cure in over 80% of chronic hepatitis C patients. In this article, we present a patient with HCV genotype 1b-induced cirrhosis with giant HCC development after ledipasvir/sofosbuvir combination therapy. Although chronic hepatitis C infection can be cured with the combination of new generation DAAs, HCC pathogenesis and development risk in cirrhotic cases are still unclear. Thus, cirrhotic patients treated with DAAs should be followed-up at close intervals after treatment.